Barts Cancer Institute sponsors the premier plenary lecture that opens the NCRI Symposium 2011. Jeff Settleman, Senior Director for Oncology Discovery at Genentech Inc reveals the cutting edge technology now being applied to identify the optimal targeted drugs for patients with a wide range of malignancies. Combining high-throughput assays with an unrivalled collection of annoted cell lines, as well as the latest -omics technology has enabled the boundaries of what is possible in drug development to be pushed beyond imagination.
Link to this comment:
All Comments (0)